Imricor Medical Systems, Inc. (ASX:IMR)
Australia flag Australia · Delayed Price · Currency is AUD
1.390
+0.045 (3.35%)
Nov 17, 2026, 11:05 AM AEDT
← View all transcripts

Earnings Call: Q3 2026

Nov 12, 2026

Summary

U.S. commercialization began with two hospital customers, and Q3 revenue exceeded five times the prior-year quarter. Regulatory progress and the Philips partnership expanded platform access, while Dallas revenue is expected in Q4.

Simon Hinsley
Executive Director, NWR Communications

Good morning, and welcome to Imricor Medical Systems' third-quarter results webinar presentation. My name is Simon Hinsley from NWR Communications, and joining me today are Imricor's President and CEO, Steve Wedan, and CFO, Jonathon Gut. Before I hand it over to Steve to go through the presentation up on the screen, I will just remind you that you can submit questions through the Q&A button on the bottom of your screen. For analysts, you can raise your hand and ask a question audibly. With that, Steve, I might just hand it over to you.

Steve Wedan
President and CEO, Imricor Medical Systems

Thank you, Simon. The third quarter that just passed was the quarter when our regulatory progress began translating into commercial traction. We now have two U.S. hospital customers. Both are among the leading children's hospitals in the United States. Revenue is up more than fivefold on the same quarter last year, despite it only reflecting one of the two NorthStar sales, because we successfully completed the installation at Dallas Children's after the period end, meaning the revenue has been recognized in the fourth quarter. On the regulatory front, 14 of 15 FDA submissions that make up our complete U.S. platform are now cleared or under review by the agency, and we have a new commercial partner standing beside us in the market, Philips, one of the largest med tech companies in the world.

Our vision is right here on the slide, and it has not changed in 20 years, to bring interventional magnetic resonance, or IMR, to every cardiac center in the world. What has changed is that this vision now has customers, a global partner, and a sales force behind it. Today, I will take you through the highlights of the quarter. Jon will then cover the financials, and I will come back to walk you through our regulatory progress, our Philips partnership, and why I believe the industry is now converging on the future we have been building. Then we will take your questions. Here is our disclaimer, which I invite you to all read at your leisure. For anyone new to the story, let me start with what Imricor actually is. We are more than a medical device company.

We are a technology platform, and we are establishing an entirely new medical field, interventional MR or IMR. In an IMR lab, real-time MR imaging replaces X-ray imaging to guide the procedures inside the heart, and in the future, inside the body more broadly. With MR, you can see soft tissue. With X-ray, you cannot. With IMR, physicians can see the heart they are treating, they can see the results of the therapy they deliver, and they can do this all with zero radiation for the patient and for the medical team. To make this possible, first we built the technology platform. That is easy to say, but it is extremely difficult to do. Too difficult, in fact, for any of the med tech giants and many smaller companies who all tried to do this over 20 years ago.

We have built the capital equipment, the software layer in our guidance system, NorthStar, and the MR-compatible consumable devices that drive our recurring revenue model. Next, we started in electrophysiology. This is an enormous and growing market, already in excess of $15 billion annually. More recently, we launched Imricor Cardiovascular, focusing on interventional cardiology, which is an entirely new market in addition to electrophysiology. In the future, we will continue to expand into neurology, oncology, and on and on. This is how a new medical field gets started. There aren't many opportunities in a lifetime to work at or invest in a company that is spearheading an entirely new field. I'm incredibly proud of what we have achieved to date and excited for the impact we can make in the global healthcare market.

Yes, it's taken a long time, but in a world where rapid, shallow moats are being disrupted faster than ever, I take comfort in the depth and breadth of the moat that we have built in terms of technology, know-how, patents, and regulatory pathways. Anyone who wants to enter our market will have to go through the same lengthy process that we are emerging from right now. This slide brings together the highlights of what's been a remarkable quarter, and the headline is right here at the top. Our U.S. commercialization launch is underway. Let's start with the commercial front. As I mentioned, we have signed our first two U.S. customers, and there are more to come. Less than a month after gaining FDA clearance for our NorthStar system, Rady Children's Hospital-San Diego led the way by establishing the first commercial IMR cardiac catheterization program in the United States.

This marked the beginning of our U.S. launch, and just two weeks later, Children's Medical Center Dallas joined in to become our second U.S. customer and the first commercial result of our compatibility with Philips, which I'll talk about in a moment. Both of those wins came through Imricor Cardiovascular, a new business vertical we launched on the back of our 3D mapping and guidance system, NorthStar, and NorthStar's FDA clearance. It opens a U.S. market of more than 250 children's hospitals and over 2,000 adult hospitals. We also partnered with DLL to launch Imricor Finance. Hospitals can now spread payments over one to seven years while Imricor is paid in full upfront, and that gives our customers real flexibility in how they adopt the technology.

On the strategic front, we received the Philips compatibility declaration following rigorous testing of all of Imricor's equipment together with the Philips MR scanners, and that opened Philips MR installed base to NorthStar for the first time in both the U.S. and in Europe. Then in late August, at the European Society of Cardiology Congress in Munich, we launched our commercial partnership with Philips by introducing the interventional MR lab solution, a turnkey cardiac IMR lab based on the Philips 1.5 Tesla BlueSeal platform. It is one of the most important things we achieved this quarter, and I'll have much more to say about that shortly, as soon as the siren goes by. All right. On the regulatory front, the pace has been relentless. We submitted all of our remaining 510(k)s.

NorthStar and the Vision-MR Diagnostic Catheter are now cleared for pediatric use, which means patients of all ages. The FDA accepted and closed the PMA manufacturing model for our Class III devices, covering seven products, including the Vision-MR Ablation Catheter. With 14 of the 15 required submissions now cleared or under review, we are very close to bringing our complete game-changing platform to patients in the United States. On the financial side, we are now at a revenue inflection point. Revenue was up $188,000 this year, or this quarter, more than five times the prior corresponding period. Yes, that is off a low base, but it is the first clear sign of our U.S. clearances turning into revenue. Dallas was installed after the quarter, so that revenue will be recognized in Q4.

We expect revenue to keep building as our installed base grows and the platform is established. We closed the quarter with over $62 million in cash, about AUD 90 million, which means we are executing this launch from a position of real financial strength. With that, I will hand it over to Jon to take you through the key numbers. Jon, over to you.

Jonathon Gut
CFO, Imricor Medical Systems

Thank you, Steve, and hello, everyone. As a reminder, all numbers are unaudited and in US dollars. We recognized revenue of $188,000 in the third quarter, a result that was driven by the sale and installation of NorthStar at our first U.S. site, Rady Children's Hospital-San Diego. Our second NorthStar sale at Children's Medical Center Dallas was installed after the quarter ended, so that revenue will be recognized in the fourth quarter. Costs continue to be well managed. We have invested in additional people across sales, marketing, manufacturing, R&D, and regulatory, and those investments are paying off. The regulatory team we bolstered during the second half of 2025 is a prime example. The additional resources added last year are contributing significantly to the regulatory momentum Steve has just highlighted.

While we have invested in additional staff, it is worth noting that the staffing costs for the quarter included approximately $1 million of non-cash stock-based compensation expense related to the vesting of performance-based stock options granted in a prior year. These stock-based compensation expenses are more fully discussed within note nine of the financial statements we included in our Form 10-Q released earlier today. Net loss for the quarter was $2.9 million, which was down 17% on the prior period. However, this decrease primarily reflects the change in fair value of the convertible notes and warrants, which are non-cash accounting adjustments. The underlying net loss, excluding these fair value adjustments, was $7.7 million. Shifting now to the balance sheet.

As Steve mentioned, we are entering this period of U.S. commercial launch with a healthy cash balance of $62.1 million, or approximately AUD 90 million at today's exchange rate. We no longer hold any marketable securities, so that balance is now reported entirely in cash and cash equivalents. Total inventory has grown to $2.6 million, up from $1.5 million at the end of last year, as we secured inventory ahead of the crucial U.S. launch. The convertible notes are recorded at their estimated fair value of approximately $29 million. Both notes are classified as current liabilities, given their maturity dates in December 2026 and March 2027. As I've noted before, the fair value is not the amount we would pay if the notes were settled in cash on their maturity dates. The outstanding principal and accrued interest for both notes was $7.1 million at September 30.

The option and warrant liabilities relate to securities issued in earlier financing rounds and are also held at fair value under US GAAP. The current portion of the option liabilities was settled during the quarter following the exercise of the underlying CDI options in July. Our operating cash outflow for the quarter amounted to approximately $7.3 million, which has increased primarily due to the staffing investments I noted earlier, while also being supported by slight increases in professional services related to product development and costs associated with our ongoing clinical trials. Proceeds from the maturity of marketable securities represent U.S. Treasury bills that were held as part of our treasury management efforts. All Treasury bills matured during the quarter, leaving our full cash balance at September 30 reported as cash and cash equivalents. Back to you, Steve.

Steve Wedan
President and CEO, Imricor Medical Systems

Thanks, Jon. Turning to our regulatory progress now. What we're doing at Imricor is unusual. Most medical device companies take a single device through the FDA and announce its approval or clearance. We're taking an entire ecosystem through various FDA approval processes concurrently. This slide 10 tracks our regulatory progress, not for a single device, but for the whole platform. This year has been extraordinary. In February, seven of our 15 submissions were cleared or sitting with the FDA. Today, it's 14 out of 15. Six device clearances are complete, two PMA modules have been reviewed and closed, six submissions are under review, and just one PMA module remains to be filed. Changing a box from yellow to green on this slide might look like a small step. It isn't. Picture a 30 cm or 12 in ruler standing upright. A stack of paper that tall is about 3,000 sheets.

The submission behind this slide would stack more than 30 rulers high, over 9 m or 30 ft of paper. I just want you to imagine the amount of work behind that much paper. I've spent a lot of time over the years telling you what an IMR lab is. We've listed a bunch of things right here. Today, I'd like to show you. This short film walks through a complete Imricor IMR lab, all the products listed on our regulatory progress slide. From the control room to the bedside, watch how every piece fits together. NorthStar controlling the MR scanner, the Advantage-MR system recording every heartbeat, and some of our catheters on the table. This is the product platform, and these are the things that we sell. That is a complete iMR lab.

Every device in that room was purpose-built to work safely inside a magnetic resonance environment, an environment that is friendly to humans with no harmful radiation, but electromagnetically hostile for normal medical devices. There is no other company in the world that can make that equipment in that room. We are IMR. This brings me to one of the most important commercial developments of our history, our partnership with Philips. We launched it together at the ESC Congress in Munich, one of the biggest cardiology meetings in the world, and two things make it powerful. First, MR compatibility. The Philips electromagnet compatibility declaration opens the Philips MR installed base to Imricor in the U.S. and in Europe for the first time. Second, a turnkey iMR lab based on the Philips 1.5 Tesla BlueSeal MR platform. That is a big deal.

A hospital can now buy a complete interventional MR solution from two companies working as one. Philips has extensive sales channels in Europe and in the U.S., which will significantly increase our reach and materially scale our rollout of the combined iMR solution. There is one more very short video I am going to share with you from the Philips' own website. Hopefully, you will recognize a lot of the Imricor technology in this clip, and I hope you will appreciate that Philips share our vision for the future of interventional medicine.

Let me unpack a few things, a few key things from that you may have missed from the clip. First, real-time interventional software interface represents years of development by Philips so that our NorthStar system can connect to the scanner, so that NorthStar can control the scanner and receive images from the scanner in real time, and so that NorthStar and our Advantage-MR system can work together with the scanner to track the location of our actively tracked catheters within a patient's body. This one is more important than it looks. Let me explain why. A conventional MR scanner holds around 1,500 L of liquid helium to cool its superconducting magnet. That makes it extremely heavy, so it typically lives on the ground floor of your hospital on reinforced concrete slabs.

Because the helium may someday need to be vented, the scanner needs a venting chimney, which we call a quench pipe, and that means it has to sit near an external wall. Those two constraints have limited where MR scanners could go in hospitals for decades. But Philips has spent years redesigning the magnet to remove these limitations. BlueSeal, their magnet, holds just 7 L of helium, permanently sealed inside the system, so it is light and it can be placed upstairs in your cardiology center. There is no quench pipe, so it does not need to be along an external wall, and you can see the blue shadow here of the former quench pipe disappearing in the video. In addition to these innovations, it is a wide-bore system for better patient access during a procedure, and importantly, at 1.5 Tesla, it does not compromise on image quality.

I've always said that we aren't bringing interventions into MRI suites. That wouldn't work because MRI suites are downstairs away from cardiology, and they were designed and installed to do diagnostic imaging. No. Instead, we're bringing MR technology into the interventional cath lab, the iMR lab. This commercial iMR lab solution is the embodiment of that goal. It's a premium, state-of-the-art iMR platform. With this introduction by Philips, a global leader in imaging is putting its name, its brand, and its sales force behind the field we created, and I particularly like how this still includes a lot of Imricor products and technology, including NorthStar on the screen. As you saw in the earlier video, there's a lot more of our equipment that sits in the control room. Finally, this is Philips' own line, it's not mine.

The future of interventional MRI is I goofed up their line. The future of intervention is MRI-guided. We've been saying that for 20 years, and this shows you that Philips believes it as well. The last thing I want to share with you is that it's not just the industry who believes this. The medical community is moving with us too. AIM IMR 2026, which is the Amsterdam International Meeting on Interventional Magnetic Resonance, is the first interventional international meeting devoted entirely to our field of IMR.

This is not an Imricor event. Imricor and Philips are co-sponsors, but it has been entirely organized by the medical community. When physicians from around the world gather to talk about nothing but interventional MR, you know the field has arrived. The thinking is shared, the execution is underway, and Imricor is at the center of both. With that, Simon, I'll hand it back to you, and we're happy to take questions.

Simon Hinsley
Executive Director, NWR Communications

Thanks for that, Steve. Just a reminder, if you did want to submit a question, the Q&A button at the bottom of your screen is the place to go. First up, we'll take a question from Tristan Maher at Jarden. Tristan, please go ahead.

Tristan Maher
Analyst, Jarden

H i, Steve. Hi, Jonathon. Just on your customers, Dallas and Rady obviously both signed up within weeks of launch. My understanding of that is that one contributing factor to this may be that they already had an MRI in the cath lab. Obviously, it is a really important issue to minimize radiation in the pediatric space in particular. Do you have any sort of indication into how prevalent this dynamic may be, where a hospital's cath lab or cardiology department more generally has sort of really good or unrestricted access to an MRI, and therefore, how many sites could be sort of converted to Imricor's equipment quite quickly, I guess, in maybe the U.S. and/or Europe?

Steve Wedan
President and CEO, Imricor Medical Systems

Tristan, that is a Let me check if I am unmuted. Yes, I am. Tristan, that is a great question. In fact, I am not in the office today. I am with the U.S. sales team at an offsite meeting, talking exactly about how we continue to refine and organize our strategy of launching throughout the U.S., including talking a lot about how we are going to partner with Philips and the work that we are already doing to partner with Philips to roll this out. Part of that is doing what you just alluded to, which is to identify where the cardiac MR centers are, who already has an MRI in their cardiology space.

Because when you have that MR in your cardiology space, that is the fastest, easiest way for us to get started, just like they did at Dallas and just like they did at Rady at San Diego. There are more. It is not just about having those be available and be in pediatric centers. This cardiac catheterization makes a lot of sense for adult hospitals too, from a financial standpoint.

Essentially, what we are doing with cardiac catheterizations is taking two procedures that you would do, MR analysis one day and pressure measurements in the cath lab, in the X-ray cath lab another day, and you are doing them both together, where you get all of the MR information that you need and all of the catheterization that you need all in one procedure. It saves time, it saves money, and it keeps the cath lab actually open and free for doing other things and generating additional revenue for the hospital. So, our pipeline of sites that are adopting the interventional cardiology, NorthStar, really for interventional cardiology purposes, is including both pediatric sites and adult sites.

One of the things that we will be working with closely is with Philips now with this partnership is identifying where, who already has an MR in their cardiology space so we can target those. It was interesting. I was in Dallas just last week, and as we are there, we are showing them some of the new software ideas that we have for interventional cardiology that will be within NorthStar.

I am talking to the doctors and so forth, and as they leave, some of the people from who are working in the lab, the MR techs, the nurses, and so forth, I hear them say, "Who are our visitors today?" They say, "Oh, yeah, those are the guys from NorthStar." That is how significant NorthStar is. They do not even know that we are from Imricor and NorthStar is our product. NorthStar is such a big deal that they think the company is NorthStar. That is the impact that this type of technology is having already in sites like this.

Tristan Maher
Analyst, Jarden

Great. Thank you. Just one more follow-up to that. Rady has kind of signaled their intent to expand from not just catheterizations, like you just mentioned, but into diagnostic EP and cardiac ablations as well. From your conversations, I guess, from your existing early customers that have already signed up or that are in the final stages of purchasing process, is this the same sort of , are they signaling the same pathway? I mean, I appreciate you cannot speak on their behalf, but also what sort of share of their pediatric volume or cath volume d o you expect, or are they signaling that they will move to MRI-based using NorthStar?

Steve Wedan
President and CEO, Imricor Medical Systems

Yeah, so if you look at a child who is often treated by a site like this for right heart, where a lot of right heart catheterizations are being performed, these are kids who were unfortunately born with hearts that are not formed properly. They will go through a series of open-heart surgeries throughout their young lives to reconstruct their heart. Every time they do one of those surgeries, there is going to be one of these right heart catheterization diagnostics before they do that. So, one of the main motivations for the interventional cardiologists at these children's hospitals is to spare the radiation exposure for these kids over and over and over again through their young lives. Then in the end, as they are younger people still, but still children, they end up with a heart that they can live with for the rest of their lives.

They have had a lot of cardiac surgery, and that cardiac surgery leaves scar tissue behind. Scar tissue on the heart is the type of thing, if you were tuned in a little bit before, you saw Gerhard Hindricks talking about substrate and scar. That same scar that will create, that can come naturally as people get older and create arrhythmias, that is going to be in these kids too. It does not really materialize as arrhythmia until they get a little bit older. So even though it is still a children's hospital, they do electrophysiology procedures to counteract this scar tissue and the substrate that is forming arrhythmia as these people get older and they are fully grown adults.

I don't want to say it wrong, but I think that the pediatric interventional cardiologist I just talked to last week at Dallas, I think he said his oldest patient was like 60 or 70 years old, and this was a pediatric patient because he's been treated by these folks his entire life. Yes, interventional cardiology at Children's Medical Center Dallas leads to electrophysiology in adult patients.

It also, if you talk to leading pediatric centers, they'll tell you very proudly that the stuff that we're doing in adults today, it all started in pediatrics. They're the ones who, out of just necessity, have blazed a way forward for treatments that are used in adults. And so you get, at Children's Medical Center Dallas, you get adult electrophysiologists from UT Southwestern, whom they're affiliated with, coming right across and watching procedures and learning how to adopt this in their own practices. It grows a bit organically from the pediatric sites as well.

Tristan Maher
Analyst, Jarden

Great. Thanks, Steve.

Simon Hinsley
Executive Director, NWR Communications

N ext up we have Nick Lau at Taylor Collison. Nick, please go ahead.

Nick Lau
Analyst, Taylor Collison

Hi, Steve and Jon. Thank you very much for your time this morning. Just a question about the Philips BlueSeal technology. How has Philips been going about marketing BlueSeal with the Imricor products? Are you seeing a step change in opportunities related to more access to BlueSeal MRIs that aren't located in ground floors? How should we see the commercial opportunity change with this partnership? The second question, if I may, is I've noted the revenues in Netherlands have recovered substantially this quarter versus the previous quarter, and also Hungary. What's the drivers behind that? Is that related to recovery of more commercial Flutter patients? If that's the case, how should we see the U.S. Flutter trial submission, given that there was a previous announcement about submitting it this month? Those are my two questions.

Steve Wedan
President and CEO, Imricor Medical Systems

Okay, Nick, let me go back to the first one, make sure I remember it properly. You're asking about BlueSeal and if we've seen a step change of the availability of those systems. Correct?

Nick Lau
Analyst, Taylor Collison

Yeah.

Steve Wedan
President and CEO, Imricor Medical Systems

Yeah, the BlueSeal magnet is relatively new, and we're launching it, they're launching it right now alongside this IMR. You can buy a BlueSeal MRI also for diagnostic imaging. But we're not finding them in the market in hospitals right now because this is something that, or at least not in great numbers, because this is something that is relatively new. But what it does is it opens up the ability for us to place MRIs in places of a hospital that they would not have been able to be placed before. That's significant because what you really want is if you have a cardiology center that has three cath labs and doing all their procedures in these three cath labs, those cath labs are all right next to each other. What we want is the IMR lab to be right there with the cath labs.

If you have to put it downstairs and by an external wall, either one of those two things will put it in a place that makes it inconvenient for the cardiology teams, for the anesthesia teams, for the nurses who work back and forth between all these labs. That makes a big difference of bringing the MR technology into the cath lab. It really is now something you can just build a lab where you want to. Instead of putting an X-ray machine in, you put an MR machine in, and you make an IMR lab instead. So it is, I wouldn't say a step change. I'd say it's the change that is happening now. Our teams are working very closely together.

Our sales and marketing leadership went to Best in the Netherlands to talk to the sales and marketing leadership at Philips to organize ourselves across Europe and the U.S. to work on the partnerships as they relate to cardiology or commercial rollout. All of that is underway. It is one of the things that we are talking with here on our internal U.S. team over the past couple of days as well. That is all happening now. More to come on this. It is going to be, I think, a pretty significant platform rollout that we are going to see over the next year, two, and three. On the revenue side of things, some of the sites, Amsterdam is one of them now, they have completed enrolling all the patients they are allowed to enroll in our Flutter trial for FDA approval.

They have rolled over now into doing commercial cases, and they will continue advancing our VT trial as well. In Hungary, it was actually a different situation where they were doing this type of thing that we have talked about lots of times, where you are doing a procedure in a lab that you are borrowing time from, and it is inconvenient logistically and so forth.

Now they have got themselves set up in a lab they have more access to, and we are excited about starting a couple of really cool initiatives there in Hungary, where not doing cases once a month because that is the only time they can get their scanner, and then make sure that that scanner day lines up with a patient coming in, but doing multiple cases each day, many days in a row, and really working on the workflow efficiency, and even potentially publishing on the output of that type of efficiency study. There is lots of cool things happening in Hungary as well.

Nick Lau
Analyst, Taylor Collison

Thanks, Steve. If I could just ask a quick follow-up, and just in regards to the Flutter trial, it is positive news that Netherlands finished enrollment. With the previous announcement that there could be a submission this month, and now with the recent update, there will be a submission of the last PMA module by the end of the trial. Was that because of the trial design or the data? I suppose trying to read the tea leaves, how should we see the submission timeline?

Steve Wedan
President and CEO, Imricor Medical Systems

Yeah. It's not about the trial design or the outcomes. It's about scheduling. I continue to be, frankly, frustrated, but sometimes we just get unlucky. A patient gets sick and doesn't get treated the day that they were scheduled, but that's the only day we've got available, and on and on. Look, it's coming to an end. We're very close to the end. We're going to wrap up the last few patients, and then we're going to submit this all to the FDA. There's nothing wrong with the trials, nothing happening that is alarming. It's just the normal process. What I have been is more, I think, open than most companies would be about when we expect the trial to wrap up, because these types of things are unpredictable.

But look, it's all moving forward, and it's very close to the end, and we will submit this data to the FDA. Look, I want everyone to keep in mind, we've already gone through this process once. All of this stuff that we're submitting to the FDA is commercially cleared in Europe. Frankly, European regulatory approval today in 2024, 2025, and 2026 with the Medical Device Regulation is really, really hard. I would say some people would say harder than it is to get FDA approval. So look, it's a rigorous process. It's a lot. It's part of what makes that deep and wide moat that I'm talking about, because anybody who comes behind us is going to have to go through this same thing. But it's all progressing. It's going just as it should. So it's just that.

Nick Lau
Analyst, Taylor Collison

Thank you so much, Steve.

Steve Wedan
President and CEO, Imricor Medical Systems

You bet, Nick.

Simon Hinsley
Executive Director, NWR Communications

Thanks, Nick. Next up, we've got Scott Power at Morgans. Scott, please go ahead.

Scott Power
Analyst, Morgans

Good day, Steve. Just a couple questions. Just in terms of the Philips strength in the U.S., just compared to the other players, if you just comment on that. And perhaps a second question, just a little bit more meat on the bone in terms of how the VT trial's going. Thanks.

Steve Wedan
President and CEO, Imricor Medical Systems

Yeah. Look, first of all, I should mention that we've got this great We've moved our partnership with Philips to a new level, to the commercial side of things. But we have strong partnerships with Siemens and with GE as well. And those, I expect, will also move in the same direction that we've moved with Philips. How they compete, there's a couple metrics you could look at. For instance, in the United States, you could say who has the biggest share of MRI systems? And that actually is irrelevant because those MRI systems are diagnostic MRs, those ones that are downstairs and by the external wall. We're building a brand new field of IMR. And one of the things that is a strength, I think, for Philips is that they are the leader across selling the X-ray systems that go into conventional cath labs.

They have the biggest touchpoint to the kinds of interventionalists who would adopt IMR as well. And that's a big part of our targeting platform. You might remember, right, that we've talked about in the beginning, we'll find cardiac MRs, and we'll turn those into IMR labs as quickly as we can. Other people may build and expand their lab spaces to include IMR.

But in the long run, what the natural turnover is as an X-ray lab burns out and needs to be re-upped, you can go with your partner, the MR vendor, and say, "For the same amount of money that you've already budgeted to put a new X-ray cath lab in, you can put an IMR lab in and take advantage of all of these, or all of the advantages that MR offers." It's good when that person that they're calling is the one that you're partnered with on a commercial basis. Again, look, I fully expect to partner with all of them on a commercial sense as well. This is so what we're doing with Philips, I think, is really just the beginning.

Scott Power
Analyst, Morgans

Right. Just a comment on the VT trial?

Steve Wedan
President and CEO, Imricor Medical Systems

Oh, yeah. Sorry. Yep. Look, we asked everyone to sort of hold off for a second on the VT trial and really focus on getting the Flutter patients done so that we can get this FDA trial wrapped up as quickly as possible. But we have VT cases on the schedule. I think the next one is happening in December. At the same time, with the Philips compatibility now complete, we are able to expand into sites that we hadn't been able to before because they're on the Philips platform. One of those is the Charité in Berlin, which is arguably one of the best hospitals in the world, certainly the top hospital across Germany. They have a Philips scanner, so all this time we've been sort of, we're waiting for our Philips compatibility to be complete so that we can get started on that platform.

They're in the process. They've upgraded their software already so that they have the right software to establish NorthStar, and we expect to get started there too. So, you might recall in the past, Scott, I've talked about how we don't want one site to just do all the patients. We have to spread it out, and there aren't that many patients in a VT trial. So, it makes sense for us to get a couple more sites up and running and then unleash everybody at the same time. So, it's coming. It hasn't been our top priority. What was our top priority last year was to do a VT case, and we've done several since then.

But to do that first in man VT case that we did last year, it checked all the boxes that anybody could have about, will this really work for a complex ablation like VT? Can you cross the septum and get from the right side of the heart to the left side of the heart? Can you properly map in the ventricle with Imricor's tools inside of this hostile electromagnetic environment of MRI? Will the ablation be durable? Can we drive a deep enough lesion into the thick muscle tissue of the ventricle? Can you do this procedure when the patient has an implantable cardioverter-defibrillator on board, or is that going to spoil all the MR images? All of that stuff was present in this case, and we checked it off.

The patient was successfully treated, is still successfully treated, and it's really very, very rewarding because the first-in-man procedure like that doesn't often go as swimmingly as this did, but just speaks to how prepared the technology was, the team was, and the quality of the team at Amsterdam University Medical Center. It was really, really cool. So, that was a big priority, but now we shift our priority as we wrap up the Flutter trial for the U.S., and we shift that priority back to VT.

Scott Power
Analyst, Morgans

Right. Thanks, Steve.

Simon Hinsley
Executive Director, NWR Communications

And just last up before we run out of time, we just got a question from Wai Sim. Wai, please go ahead.

Speaker 7

Thanks. Can you guys hear me?

Simon Hinsley
Executive Director, NWR Communications

Yep.

Steve Wedan
President and CEO, Imricor Medical Systems

Sure can.

Speaker 7

Okay, great. I have a few questions, but the first one is just in regards to Europe at the moment. We saw about a third of the revenues come through from Europe. Can you talk a bit about how, I guess, the development in Europe as well as the Middle East is progressing at this point in time?

Steve Wedan
President and CEO, Imricor Medical Systems

Yeah. We have had to, I know this is a tired story, because the pandemic was quite a while ago, but before, when we first launched in Europe, I had spent years of R&D. We had spent years of R&D development work across Europe doing a couple things, both getting key opinion leader sites up and running and doing procedures, but also spreading the word and getting others interested in what's happening and putting those people in touch, and what I like to call seeding the market, getting it primed and ready for adoption. When we launched, gosh, it happened just like we would expect. We had site after site that was just ramping up. That took years and years to do.

After the pandemic wrapped up and financial situations, the dust cleared and the strains on capital budgets were starting to get alleviated, we had to start that process over again because the doctors all moved. The practice has changed. Some people are tearing down the buildings that we were working in. They are building brand new cardiology centers across the street. So, we had to start that process again of priming and seeding the market, and that is what we have been doing for the past, well, year. Look, I think everyone is tired of me saying the pipeline is robust and growing. I am excited to show you what that is going to mean, and we will be able to show you that very soon. But internally, we can see all the things moving in the direction. Nothing is at a standstill. Nothing is moving in the wrong direction.

It just takes some time to get this started. When you are doing something as significant as what we are doing, there has always been a chicken-and-egg problem where we have made devices that work in a lab that nobody has adopted yet. So, we have to get the devices approved and the labs established at the same time. You question the motivation of somebody to build a lab when there are not any devices yet, and build devices when labs do not exist.

So, we do them simultaneously. It just takes some time. But once that ship starts to turn, the momentum is tremendous. Look at the Amsterdam University Medical Center. They have, I think this month they are opening, actually, I am sure this month, they are opening their new cardiology center. The center of that new cardiology center, it is a brand new wing, it has been in construction for years.

At the center of that is an IMR lab built on the Philips platform that you saw just a second ago. That momentum has been coming all this time, but now it is there. That is sort of the first output sign of this priming of the market that we have had. Once that lab is established, they will do some diagnostic imaging, but it is there for interventions. So we have now, call it an annuity of procedures that will be performed in that lab for 10, 15 years. That is the kind of momentum that once, like I said, it starts to turn, it stays in that direction.

Speaker 7

My next question is just in regards to the Philips BlueSeal MRIs. I mean, looks like game-changing technology that they have got there. Are you seeing other vendors following in their footsteps and developing similar type of solutions such that we can really see Imricor's, I guess, solutions rolled out to other vendors outside of Philips over the medium term?

Steve Wedan
President and CEO, Imricor Medical Systems

Yep, absolutely.

Speaker 7

Okay, great. The other thing, I have seen recently that Philips, there has been some things around the recalls of their X-ray fluoroscopy. Is that something that you think could help accelerate the adoption of Imricor over the short term?

Steve Wedan
President and CEO, Imricor Medical Systems

Yeah, I do not have a great answer to that question. I think that this is the way we are growing the adoption is just by awareness of the idea that, one, what we have been talking about for years and what has been sort of seen as a research project, where you had to cobble together, you buy an MR scanner from this guy, you buy in-room monitors from that person, you get Imricor's equipment, you bring all these people together, and you do something unusual. Now, it is usual, it is normal. There is a commercial lab set that you can buy that legitimizes the whole field, and that is what we see as creating the momentum that this field is gaining.

Simon Hinsley
Executive Director, NWR Communications

That concludes the Q&A segment. Steve, I might just hand it back to you for closing remarks on this slide.

Steve Wedan
President and CEO, Imricor Medical Systems

All right, thanks. Look, I would like to bring it all together with seven reasons I have written down here why I have never been more confident in Imricor. One, we are the global leader in MR Conditional systems and devices for cardiac intervention. That is undeniable. Two, we are entering a $15 billion U.S. market that is growing at around 15% a year. We do not need to create this market. It already exists, and it is growing fast. Three, there is no one else who offers what we offer.

There is no competing platform. Four, the radiation awareness and safety have become a tailwind for us. In July, six of the world's leading medical societies called for urgent action on radiation protection in cath labs. While others try to shield people from radiation, we remove it altogether. The fifth one is we have a close partnership now with the MR manufacturers. I talked about Philips today, and you have seen what that looks like.

We will do that also with especially GE and Siemens. Six, we have a strong balance sheet with $62 million or AUD 89 million at September 30. Seven, we are commercializing now in the United States, right now. Thank you, everyone, for your time, attention, and support. I look forward to keeping you up to date on our ongoing regulatory and commercial progress over the remainder of the year and well into 2027. Have a good rest of your day.